Ryvu Therapeutics Reports 2021 Half-Year Financial Results

Read More

Ryvu Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors and CMO Transition

Read More

Ryvu Therapeutics publishes MCT4 inhibitors research paper in the Journal of Medicinal Chemistry

Read More

Ryvu Therapeutics to participate in upcoming global investor conferences

Read More

FDA lifts Partial Clinical Hold on Phase Ib Clinical Trial of RVU120 (SEL120) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Read More

Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual EHA Congress. Phase I/II Data for SEL24 (MEN1703) presented by development partner Menarini.

Read More

Representatives of the Ministry of Economic Development, Labour and Technology visited Ryvu Therapeutics

Read More

Ryvu Therapeutics among the founding members of 30% Club Poland

Read More

Discussion On Ryvu Data Presented at EHA 2021 – Conference Call

Read More

Synthetic lethality in cancer treatment – Ryvu Therapeutics seminar

Read More